Trial Profile
A Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 1% and 3% Topical MIinocycline Gel (HY01) in Patients With Papulopustular Rosacea
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Minocycline (Primary)
- Indications Rosacea
- Focus Therapeutic Use
- Acronyms MARS
- Sponsors Hovione
- 06 Jan 2020 Primary endpoint has been met. (Change in Lesion Count)
- 06 Jan 2020 Results published in the British Journal of Dermatology
- 01 Nov 2019 Status changed from active, no longer recruiting to completed.